Evercore ISI Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective reduced by analysts at Evercore ISI from $5.00 to $4.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “in-line” rating on the stock. Evercore ISI’s price objective indicates a potential upside of 0.25% from the stock’s current price.

A number of other brokerages have also commented on HCAT. KeyCorp lowered their price objective on Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, April 16th. BTIG Research lowered Health Catalyst from a “buy” rating to a “neutral” rating in a report on Tuesday, June 17th. Citigroup lowered their price objective on Health Catalyst from $7.00 to $6.50 and set a “buy” rating on the stock in a report on Friday, April 25th. Canaccord Genuity Group lowered their target price on Health Catalyst from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Finally, Stifel Nicolaus raised their target price on Health Catalyst from $5.00 to $5.50 and gave the company a “hold” rating in a report on Thursday, May 8th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Health Catalyst Stock Performance

Shares of NASDAQ HCAT opened at $3.99 on Wednesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.24 and a current ratio of 1.24. The firm has a market cap of $277.70 million, a price-to-earnings ratio of -3.47 and a beta of 1.51. The business’s 50-day simple moving average is $3.93 and its 200-day simple moving average is $4.69. Health Catalyst has a 52 week low of $3.49 and a 52 week high of $9.24.

Institutional Trading of Health Catalyst

A number of hedge funds have recently modified their holdings of the company. First Light Asset Management LLC lifted its position in shares of Health Catalyst by 99.1% in the 1st quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company’s stock worth $47,279,000 after acquiring an additional 5,195,686 shares during the period. Daventry Group LP lifted its position in shares of Health Catalyst by 3.8% in the 4th quarter. Daventry Group LP now owns 2,509,480 shares of the company’s stock worth $17,742,000 after acquiring an additional 91,878 shares during the period. Nepsis Inc. lifted its position in shares of Health Catalyst by 2,072.1% in the 1st quarter. Nepsis Inc. now owns 2,090,812 shares of the company’s stock worth $9,471,000 after acquiring an additional 1,994,555 shares during the period. Alyeska Investment Group L.P. lifted its position in shares of Health Catalyst by 74.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after acquiring an additional 861,150 shares during the period. Finally, Primecap Management Co. CA lifted its position in shares of Health Catalyst by 3.8% in the 1st quarter. Primecap Management Co. CA now owns 2,005,116 shares of the company’s stock worth $9,083,000 after acquiring an additional 72,499 shares during the period. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.